Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Current Deferred Revenue (2022 - 2024)

Century Therapeutics (IPSC) has disclosed Current Deferred Revenue for 3 consecutive years, with $109.2 million as the latest value for Q4 2024.

  • Quarterly Current Deferred Revenue rose 2396.89% to $109.2 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $109.2 million through Dec 2024, up 2396.89% year-over-year, with the annual reading at $109.2 million for FY2024, 2396.89% up from the prior year.
  • Current Deferred Revenue for Q4 2024 was $109.2 million at Century Therapeutics, up from $3.6 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $109.2 million in Q4 2024, with the low at $3.6 million in Q3 2024.
  • Average Current Deferred Revenue over 3 years is $14.4 million, with a median of $6.4 million recorded in 2022.
  • The sharpest move saw Current Deferred Revenue crashed 48.87% in 2023, then soared 2396.89% in 2024.
  • Over 3 years, Current Deferred Revenue stood at $7.2 million in 2022, then tumbled by 38.89% to $4.4 million in 2023, then skyrocketed by 2396.89% to $109.2 million in 2024.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $109.2 million, $3.6 million, and $4.4 million for Q4 2024, Q3 2024, and Q2 2024 respectively.